Template:Amiodarone adverse effects: Difference between revisions
No edit summary |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
===[[Amiodarone]] Adverse Effects=== | |||
*[[Bradycardia]] | *[[Bradycardia]] | ||
*Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. | *Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. | ||
| Line 8: | Line 9: | ||
*Drug-induced destructive thyroiditis | *Drug-induced destructive thyroiditis | ||
**More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone. | **More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone. | ||
*[[Amiodarone | *[[Amiodarone pulmonary toxicity]] | ||
*Hyperpigmentation rash[[File:Amiodarone_hyperpigmentation.jpg|thumbnail]] | *Hyperpigmentation rash[[File:Amiodarone_hyperpigmentation.jpg|thumbnail]] | ||
Latest revision as of 20:11, 24 April 2024
Amiodarone Adverse Effects
- Bradycardia
- Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation.
- Prolonged QT
- Thyrotoxicosis[1]
- Between 5-20% of patients treated with amiodarone have thyrotoxicosis (higher in areas of iodine deficiency)
- Iodine-induced hyperthyroidism
- It is thought that the iodine load may unmask hyperthyroidism in patients with multinodular goiter and subclinical Graves’ disease
- Drug-induced destructive thyroiditis
- More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone.
- Amiodarone pulmonary toxicity
- Hyperpigmentation rash
- ↑ Rosen's 8th Edition